Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 105

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 105
---
overa° decreased 2% and was flat in the three and six months ended June 30, 2025 versus 2024, respectively, driven by decreases in Smart Tip net selling prices per unit of 7% and 3%, partially offset by increases in Smart Tip volume of 4% and 2%.

Bupivacaine liposome injectable suspension revenue decreased 84% and 45% in the three and six months ended June 30, 2025 versus 2024, respectively, due to timing of orders placed. Its related royalties decreased 54% and 29% in the three and six months ended June 30, 2025 versus 2024, respectively, primarily due to both the timing of orders placed for veterinary use and the sales mix of vial sizes.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 46

The following tables provide a summary of activity with respect to our sales-related allowances and accruals related to EXPAREL and ZILRETTA for the six months ended June 30, 2025 and 2024 (in thousands):

June 30, 2025ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2024$1,600 $1,308 $4,875 $4,863 $1,707 $14,353 Provision702 6,918 11,189 76,044 1,813 96,666 Payments(267)(6,838)(11,320)(76,113)(1,815)(96,353)Balance at June 30, 2025$2,035 $1,388 $4,744 $4,794 $1,705 $14,666 

June 30, 2024ReturnsAllowancesPromptPaymentDiscountsServiceFeesVolumeRebates andChargebacksGovernmentRebatesTotalBalance at December 31, 2023$1,868 $1,308 $3,697 $5,870 $1,175 $13,918 Provision1,014 6,199 9,985 54,533 1,334 73,065 Payments(664)(6,287)(9,850)(55,058)(715)(